BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 28745327)

  • 1. Seminal vesicle fluid increases the efficacy of intravaginal HSV-2 vaccination.
    Varese A; Remes Lenicov F; Gonzalez Prinz M; Paletta A; Ernst G; Maeto C; Merlotti A; Sabatte J; Símula S; Holgado MP; Dantas E; Geffner J; Ceballos A
    Mucosal Immunol; 2018 Mar; 11(2):536-548. PubMed ID: 28745327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Role for Interleukin-17 in Enhancing Type 1 Helper T Cell Immunity in the Female Genital Tract following Mucosal Herpes Simplex Virus 2 Vaccination.
    Bagri P; Anipindi VC; Nguyen PV; Vitali D; Stämpfli MR; Kaushic C
    J Virol; 2017 Dec; 91(23):. PubMed ID: 28956763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of herpes simplex virus-specific T cells in the murine female genital tract following genital infection with herpes simplex virus type 2.
    Milligan GN; Bernstein DI
    Virology; 1995 Oct; 212(2):481-9. PubMed ID: 7571418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaginal submucosal dendritic cells, but not Langerhans cells, induce protective Th1 responses to herpes simplex virus-2.
    Zhao X; Deak E; Soderberg K; Linehan M; Spezzano D; Zhu J; Knipe DM; Iwasaki A
    J Exp Med; 2003 Jan; 197(2):153-62. PubMed ID: 12538655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T lymphocytes are required for protection of the vaginal mucosae and sensory ganglia of immune mice against reinfection with herpes simplex virus type 2.
    Milligan GN; Bernstein DI; Bourne N
    J Immunol; 1998 Jun; 160(12):6093-100. PubMed ID: 9637526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the genital tract mucosa with a lipopeptide/recombinant adenovirus prime/boost vaccine induces potent and long-lasting CD8+ T cell immunity against herpes: importance of MyD88.
    Zhang X; Dervillez X; Chentoufi AA; Badakhshan T; Bettahi I; Benmohamed L
    J Immunol; 2012 Nov; 189(9):4496-509. PubMed ID: 23018456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estradiol Enhances Antiviral CD4
    Bagri P; Ghasemi R; McGrath JJC; Thayaparan D; Yu E; Brooks AG; Stämpfli MR; Kaushic C
    J Virol; 2020 Dec; 95(1):. PubMed ID: 33028712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topical herpes simplex virus 2 (HSV-2) vaccination with human papillomavirus vectors expressing gB/gD ectodomains induces genital-tissue-resident memory CD8+ T cells and reduces genital disease and viral shedding after HSV-2 challenge.
    Çuburu N; Wang K; Goodman KN; Pang YY; Thompson CD; Lowy DR; Cohen JI; Schiller JT
    J Virol; 2015 Jan; 89(1):83-96. PubMed ID: 25320297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravaginal infection with herpes simplex virus type-2 (HSV-2) generates a functional effector memory T cell population that persists in the murine genital tract.
    Tang VA; Rosenthal KL
    J Reprod Immunol; 2010 Dec; 87(1-2):39-44. PubMed ID: 20688399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enrichment of herpes simplex virus type 2 (HSV-2) reactive mucosal T cells in the human female genital tract.
    Posavad CM; Zhao L; Dong L; Jin L; Stevens CE; Magaret AS; Johnston C; Wald A; Zhu J; Corey L; Koelle DM
    Mucosal Immunol; 2017 Sep; 10(5):1259-1269. PubMed ID: 28051084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of HSV-specific CD4+ Th1 responses and CD8+ cytotoxic T lymphocytes with antiviral activity by vaccination with the HSV-2 mutant ICP10DeltaPK.
    Gyotoku T; Ono F; Aurelian L
    Vaccine; 2002 Jun; 20(21-22):2796-807. PubMed ID: 12034107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation of humoral immune responses against herpes simplex virus type 2 in the murine female genital tract.
    Milligan GN; Bernstein DI
    Virology; 1995 Jan; 206(1):234-41. PubMed ID: 7831778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaginal memory T cells induced by intranasal vaccination are critical for protective T cell recruitment and prevention of genital HSV-2 disease.
    Sato A; Suwanto A; Okabe M; Sato S; Nochi T; Imai T; Koyanagi N; Kunisawa J; Kawaguchi Y; Kiyono H
    J Virol; 2014 Dec; 88(23):13699-708. PubMed ID: 25231301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A role for the CCR5-CCL5 interaction in the preferential migration of HSV-2-specific effector cells to the vaginal mucosa upon nasal immunization.
    Joo S; Suwanto A; Sato A; Nakahashi-Ouchida R; Mori H; Uchida Y; Sato S; Kurashima Y; Yuki Y; Fujihashi K; Kawaguchi Y; Kiyono H
    Mucosal Immunol; 2019 Nov; 12(6):1391-1403. PubMed ID: 31551493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term immunity and protection against herpes simplex virus type 2 in the murine female genital tract after mucosal but not systemic immunization.
    Gallichan WS; Rosenthal KL
    J Infect Dis; 1998 May; 177(5):1155-61. PubMed ID: 9592997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A mouse model for studies of mucosal immunity to vaginal infection by herpes simplex virus type 2.
    Parr MB; Kepple L; McDermott MR; Drew MD; Bozzola JJ; Parr EL
    Lab Invest; 1994 Mar; 70(3):369-80. PubMed ID: 8145530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of interleukin-15 compromises CD4-dependent adaptive immune responses against herpes simplex virus 2.
    Gill N; Ashkar AA
    J Virol; 2009 Jan; 83(2):918-26. PubMed ID: 19004955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Laser Adjuvant-Assisted Peptide Vaccine Promotes Skin Mobilization of Dendritic Cells and Enhances Protective CD8
    Lopes PP; Todorov G; Pham TT; Nesburn AB; Bahraoui E; BenMohamed L
    J Virol; 2018 Apr; 92(8):. PubMed ID: 29437976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of genital T cell responses to herpes simplex virus type 2 resulting from immunization of the nasal mucosa.
    Milligan GN; Dudley-McClain KL; Chu CF; Young CG
    Virology; 2004 Jan; 318(2):507-15. PubMed ID: 14972519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A genital tract peptide epitope vaccine targeting TLR-2 efficiently induces local and systemic CD8+ T cells and protects against herpes simplex virus type 2 challenge.
    Zhang X; Chentoufi AA; Dasgupta G; Nesburn AB; Wu M; Zhu X; Carpenter D; Wechsler SL; You S; BenMohamed L
    Mucosal Immunol; 2009 Mar; 2(2):129-143. PubMed ID: 19129756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.